Morgan Stanley’s Oragenics OGEN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-138
Closed -$108 8445
2025
Q4
$108 Hold
138
﹤0.01% 7700
2025
Q3
$181 Sell
138
-11,774
-99% -$14.9K ﹤0.01% 7610
2025
Q2
$45.5K Buy
11,912
+11,759
+7,686% +$59.6K ﹤0.01% 6388
2025
Q1
$965 Buy
153
+8
+6% +$69 ﹤0.01% 7286
2024
Q4
$1.6K Buy
145
+112
+339% +$1.15K ﹤0.01% 7228
2024
Q3
$382 Buy
+33
New +$931 ﹤0.01% 7327
2024
Q2
Hold
0
7839
2024
Q1
Hold
0
-$46 7930
2023
Q4
Hold
0
7678
2023
Q1
Hold
0
-$1 7798
2022
Q4
Hold
0
7873
2022
Q3
Hold
0
7823
2022
Q2
Hold
0
7922
2022
Q1
Hold
0
8068
2021
Q4
Hold
0
8066
2020
Q2
Hold
0
6684
2020
Q1
Hold
0
6658
2019
Q4
Hold
0
6723
2019
Q3
Hold
0
6713
2018
Q3
Sell
-43
Closed -$107K 6768
2018
Q2
$107K Buy
+43
New +$113K ﹤0.01% 5727
2017
Q4
Hold
0
6618
2017
Q3
Hold
0
6583
2017
Q2
Hold
0
6628
2017
Q1
Hold
0
6597
2016
Q4
Hold
0
6548
2016
Q3
Hold
0
6543
2016
Q2
Hold
0
6605
2016
Q1
Hold
0
6477
2015
Q4
Hold
0
6510
2015
Q3
Hold
0
6544
2015
Q2
Hold
0
6715
2015
Q1
Hold
0
6616
2014
Q4
Hold
0
6635
2014
Q3
Hold
0
6628
2014
Q2
Hold
0
6438
2014
Q1
Hold
0
6398

Other funds holding OGEN

Morgan Stanley's OGEN Position: Q1 2026 in Review

Morgan Stanley sold out of Oragenics (OGEN) in Q1 2026, closing a stake of 138 shares — an estimated $108 sold.

Morgan Stanley first reported a position in OGEN in Q2 2018 and held it in 7 quarters. The position peaked at $107K in Q2 2018. 19 funds tracked by Wall St. Rank hold OGEN as of Q1 2026.

  • Morgan Stanley reported no remaining Oragenics position as of Q1 2026 after selling out during the quarter.
  • Morgan Stanley sold 138 Oragenics shares in Q1 2026, an estimated $108.
  • Morgan Stanley first reported a position in Oragenics in Q2 2018 and held it in 7 quarters.
  • Morgan Stanley's Oragenics position peaked at $107K in Q2 2018.
  • 19 funds tracked by Wall St. Rank held Oragenics as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.